154 related articles for article (PubMed ID: 12805062)
1. A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia.
Ehrhardt A; Xu H; Dillow AM; Bellinger DA; Nichols TC; Kay MA
Blood; 2003 Oct; 102(7):2403-11. PubMed ID: 12805062
[TBL] [Abstract][Full Text] [Related]
2. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy.
Mount JD; Herzog RW; Tillson DM; Goodman SA; Robinson N; McCleland ML; Bellinger D; Nichols TC; Arruda VR; Lothrop CD; High KA
Blood; 2002 Apr; 99(8):2670-6. PubMed ID: 11929752
[TBL] [Abstract][Full Text] [Related]
3. Helper-dependent adenoviral gene therapy mediates long-term correction of the clotting defect in the canine hemophilia A model.
McCORMACK WM; Seiler MP; Bertin TK; Ubhayakar K; Palmer DJ; Ng P; Nichols TC; Lee B
J Thromb Haemost; 2006 Jun; 4(6):1218-1225. PubMed ID: 16706963
[TBL] [Abstract][Full Text] [Related]
4. Sustained phenotypic correction of canine hemophilia B after systemic administration of helper-dependent adenoviral vector.
Brunetti-Pierri N; Nichols TC; McCorquodale S; Merricks E; Palmer DJ; Beaudet AL; Ng P
Hum Gene Ther; 2005 Jul; 16(7):811-20. PubMed ID: 16000063
[TBL] [Abstract][Full Text] [Related]
5. Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A.
Brown BD; Shi CX; Powell S; Hurlbut D; Graham FL; Lillicrap D
Blood; 2004 Feb; 103(3):804-10. PubMed ID: 14512318
[TBL] [Abstract][Full Text] [Related]
6. Hyperactive sleeping beauty transposase enables persistent phenotypic correction in mice and a canine model for hemophilia B.
Hausl MA; Zhang W; Müther N; Rauschhuber C; Franck HG; Merricks EP; Nichols TC; Kay MA; Ehrhardt A
Mol Ther; 2010 Nov; 18(11):1896-906. PubMed ID: 20717103
[TBL] [Abstract][Full Text] [Related]
7. Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression.
Fang B; Eisensmith RC; Wang H; Kay MA; Cross RE; Landen CN; Gordon G; Bellinger DA; Read MS; Hu PC
Hum Gene Ther; 1995 Aug; 6(8):1039-44. PubMed ID: 7578416
[TBL] [Abstract][Full Text] [Related]
8. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver.
Wang L; Nichols TC; Read MS; Bellinger DA; Verma IM
Mol Ther; 2000 Feb; 1(2):154-8. PubMed ID: 10933925
[TBL] [Abstract][Full Text] [Related]
9. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs.
Kay MA; Landen CN; Rothenberg SR; Taylor LA; Leland F; Wiehle S; Fang B; Bellinger D; Finegold M; Thompson AR
Proc Natl Acad Sci U S A; 1994 Mar; 91(6):2353-7. PubMed ID: 8134398
[TBL] [Abstract][Full Text] [Related]
10. Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs.
Gallo-Penn AM; Shirley PS; Andrews JL; Tinlin S; Webster S; Cameron C; Hough C; Notley C; Lillicrap D; Kaleko M; Connelly S
Blood; 2001 Jan; 97(1):107-13. PubMed ID: 11133749
[TBL] [Abstract][Full Text] [Related]
11. Hepatic gene therapy for haemophilia B.
Kay MA
Haemophilia; 1998 Jul; 4(4):389-92. PubMed ID: 9873759
[TBL] [Abstract][Full Text] [Related]
12. Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy.
Wang L; Calcedo R; Nichols TC; Bellinger DA; Dillow A; Verma IM; Wilson JM
Blood; 2005 Apr; 105(8):3079-86. PubMed ID: 15637142
[TBL] [Abstract][Full Text] [Related]
13. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation.
Herzog RW; Mount JD; Arruda VR; High KA; Lothrop CD
Mol Ther; 2001 Sep; 4(3):192-200. PubMed ID: 11545609
[TBL] [Abstract][Full Text] [Related]
14. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia.
Monahan PE; Samulski RJ; Tazelaar J; Xiao X; Nichols TC; Bellinger DA; Read MS; Walsh CE
Gene Ther; 1998 Jan; 5(1):40-9. PubMed ID: 9536263
[TBL] [Abstract][Full Text] [Related]
15. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy.
Niemeyer GP; Herzog RW; Mount J; Arruda VR; Tillson DM; Hathcock J; van Ginkel FW; High KA; Lothrop CD
Blood; 2009 Jan; 113(4):797-806. PubMed ID: 18957684
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
Chuah MK; Schiedner G; Thorrez L; Brown B; Johnston M; Gillijns V; Hertel S; Van Rooijen N; Lillicrap D; Collen D; VandenDriessche T; Kochanek S
Blood; 2003 Mar; 101(5):1734-43. PubMed ID: 12406898
[TBL] [Abstract][Full Text] [Related]
17. Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B.
Harding TC; Koprivnikar KE; Tu GH; Zayek N; Lew S; Subramanian A; Sivakumaran A; Frey D; Ho K; VanRoey MJ; Nichols TC; Bellinger DA; Yendluri S; Waugh J; McArthur J; Veres G; Donahue BA
Gene Ther; 2004 Jan; 11(2):204-13. PubMed ID: 14712305
[TBL] [Abstract][Full Text] [Related]
18. Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors.
Chao H; Monahan PE; Liu Y; Samulski RJ; Walsh CE
Mol Ther; 2001 Sep; 4(3):217-22. PubMed ID: 11545612
[TBL] [Abstract][Full Text] [Related]
19. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors.
Snyder RO; Miao CH; Patijn GA; Spratt SK; Danos O; Nagy D; Gown AM; Winther B; Meuse L; Cohen LK; Thompson AR; Kay MA
Nat Genet; 1997 Jul; 16(3):270-6. PubMed ID: 9207793
[TBL] [Abstract][Full Text] [Related]
20. Persistent expression of canine factor IX in hemophilia B canines.
Chao H; Samulski R; Bellinger D; Monahan P; Nichols T; Walsh C
Gene Ther; 1999 Oct; 6(10):1695-704. PubMed ID: 10516718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
